Last edition
News about "brelovitug"
Mirum's Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta
Mirum Pharmaceuticals reports positive Phase 3 AZURE-1 results for brelovitug, with the investigational antibody meeting its primary endpoint in chronic HDV.
Brelovitug | 29/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members